192 related articles for article (PubMed ID: 26861249)
21. Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells.
Ali JL; Lagasse BJ; Minuk AJ; Love AJ; Moraya AI; Lam L; Arthur G; Gibson SB; Morrison LC; Werbowetski-Ogilvie TE; Fu Y; Nachtigal MW
Int J Cancer; 2015 Mar; 136(5):E455-69. PubMed ID: 25227893
[TBL] [Abstract][Full Text] [Related]
22. The anti-cancer effects of itraconazole in epithelial ovarian cancer.
Choi CH; Ryu JY; Cho YJ; Jeon HK; Choi JJ; Ylaya K; Lee YY; Kim TJ; Chung JY; Hewitt SM; Kim BG; Bae DS; Lee JW
Sci Rep; 2017 Jul; 7(1):6552. PubMed ID: 28747628
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
[TBL] [Abstract][Full Text] [Related]
24. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
[TBL] [Abstract][Full Text] [Related]
25. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
26. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.
Hiramatsu K; Serada S; Enomoto T; Takahashi Y; Nakagawa S; Nojima S; Morimoto A; Matsuzaki S; Yokoyama T; Takahashi T; Fujimoto M; Takemori H; Ueda Y; Yoshino K; Morii E; Kimura T; Naka T
Cancer Res; 2018 Jan; 78(2):516-527. PubMed ID: 29187404
[TBL] [Abstract][Full Text] [Related]
27. Novel Nano-Therapeutic Approach Actively Targets Human Ovarian Cancer Stem Cells after Xenograft into Nude Mice.
Abou-ElNaga A; Mutawa G; El-Sherbiny IM; Abd-ElGhaffar H; Allam AA; Ajarem J; Mousa SA
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417924
[TBL] [Abstract][Full Text] [Related]
28. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
[TBL] [Abstract][Full Text] [Related]
29. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
[TBL] [Abstract][Full Text] [Related]
30. Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Wei H; Hellström KE; Hellström I
Gynecol Oncol; 2012 Jun; 125(3):727-33. PubMed ID: 22430613
[TBL] [Abstract][Full Text] [Related]
31. Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer.
Zhang L; Zhou D; Guan W; Ren W; Sun W; Shi J; Lin Q; Zhang J; Qiao T; Ye Y; Wu Y; Zhang Y; Zuo X; Connor KL; Xu G
Cell Death Dis; 2017 Dec; 8(12):3214. PubMed ID: 29238081
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic efficacy and molecular mechanisms of snake (Walterinnesia aegyptia) venom-loaded silica nanoparticles in the treatment of breast cancer- and prostate cancer-bearing experimental mouse models.
Badr G; Al-Sadoon MK; Rabah DM
Free Radic Biol Med; 2013 Dec; 65():175-189. PubMed ID: 23811005
[TBL] [Abstract][Full Text] [Related]
33. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
[TBL] [Abstract][Full Text] [Related]
34. Restoration of paclitaxel resistance by CDK1 intervention in drug-resistant ovarian cancer.
Bae T; Weon KY; Lee JW; Eum KH; Kim S; Choi JW
Carcinogenesis; 2015 Dec; 36(12):1561-71. PubMed ID: 26442525
[TBL] [Abstract][Full Text] [Related]
35. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway.
Zhang N; Qiu J; Zheng T; Zhang X; Hua K; Zhang Y
Oncol Rep; 2018 Mar; 39(3):1034-1042. PubMed ID: 29286125
[TBL] [Abstract][Full Text] [Related]
36. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer.
Wahba J; Natoli M; Whilding LM; Parente-Pereira AC; Jung Y; Zona S; Lam EW; Smith JR; Maher J; Ghaem-Maghami S
Cancer Immunol Immunother; 2018 Nov; 67(11):1753-1765. PubMed ID: 30167862
[TBL] [Abstract][Full Text] [Related]
38. Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.
Li H; Qian Y; Wang X; Pi R; Zhao X; Wei X
Cell Prolif; 2020 Jan; 53(1):e12719. PubMed ID: 31778258
[TBL] [Abstract][Full Text] [Related]
39. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
[TBL] [Abstract][Full Text] [Related]
40. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
